Nymox Pharmaceutical Corp

Company Profile

Nymox Pharmaceutical Corp had its IPO on 1997-12-22 under the ticker symbol NYMX.

The company operates in the LIFE SCIENCES sector and IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry. Nymox Pharmaceutical Corp has a staff strength of 0 employees.

Stock update

Shares of Nymox Pharmaceutical Corp opened at $0.36 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $0.34 - $0.36, and closed at $0.35.

This is a -2.14% slip from the previous day's closing price.

A total volume of 73,347 shares were traded at the close of the day’s session.

In the last one week, shares of Nymox Pharmaceutical Corp have increased by 0%.

Nymox Pharmaceutical Corp's Key Ratios

Nymox Pharmaceutical Corp has a market cap of $0.032 billion, indicating a price to book ratio of 14.56 and a price to sales ratio of 25395.11.

In the last 12-months Nymox Pharmaceutical Corp’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.013 billion. The EBITDA ratio measures Nymox Pharmaceutical Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Nymox Pharmaceutical Corp’s operating margin was 0% while its return on assets stood at -145.2% with a return of equity of -284%.

In Q2, Nymox Pharmaceutical Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Nymox Pharmaceutical Corp’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

0

Its diluted EPS in the last 12-months stands at $-0.183 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nymox Pharmaceutical Corp’s profitability.

Nymox Pharmaceutical Corp stock is trading at a EV to sales ratio of 28731.51 and a EV to EBITDA ratio of -2.264. Its price to sales ratio in the trailing 12-months stood at 25395.11.

Nymox Pharmaceutical Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

Nymox Pharmaceutical Corp ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Nymox Pharmaceutical Corp ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Nymox Pharmaceutical Corp’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Nymox Pharmaceutical Corp's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Nymox Pharmaceutical Corp paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$0.35

52-Week High

$2.1

52-Week Low

$0.19

Analyst Target Price

$10.25

Nymox Pharmaceutical Corp stock is currently trading at $0.35 per share. It touched a 52-week high of $2.1 and a 52-week low of $2.1. Analysts tracking the stock have a 12-month average target price of $10.25.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.